Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.39 |
| ▸ | DRD5 | P21918 | 9/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.39 |
| ▸ | DRD3 | P35462 | 8/20 | 0.39 |
| ▸ | DRD4 | P21917 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082480 | 1.00 | DRD1 (0.39) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL14082458 | 0.94 | DRD2 (0.41) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL14082472 | 0.86 | DRD1 (0.36) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL14082460 | 0.86 | DRD1 (0.36) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL6617111 | 0.83 | DRD2 (0.38) | DRD1DRD2DRD3DRD4 | |
| SCHEMBL6615109 | 0.80 | HSD17B10 (0.33) | — | |
| SCHEMBL4874428 | 0.78 | MAPT (0.43) | — | |
| SCHEMBL4872690 | 0.78 | MAPT (0.43) | — | |
| SCHEMBL14573385 | 0.75 | CHRM1 (0.38) | DRD3CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5635580 | 0.75 | CHRM1 (0.38) | DRD3CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | DRD1 1133/4885DRD5 1307/4885DRD2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.